In our clinic, we often see women with symptoms of depression and anxiety which emerge in the context of the menopausal transition; many of these women have suffered for years with severe symptoms before seeking [...]
We completed our first MGH Women’s Mental Health online CME program in the Fall of 2019, and we are excited to offer the next round of the course in the series. Thank you for those [...]
The American College of Obstetricians and Gynecologists (ACOG) now recommends screening for perinatal depression, stating that “clinicians screen patients at least once during the perinatal period for depression and anxiety symptoms using a standard, validated [...]
While we have considerable data regarding the reproductive safety of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs), most studies have focused on the prevalence of major malformations in children with prenatal exposure to antidepressants. [...]
After accidental deaths, suicide is the second leading cause of death in those between the ages of 10 and 19 years. HIstorically, suicide rates have been higher for male than for female youth; however, [...]
We are excited to offer the next round of the MGH Women’s Mental Health online CME program. Thank you for those who participated in the fall. The next course starts February 10, and we can [...]
We hope everybody is settling into the New Year. Here's a look back at what happened in 2019. Brexanolone takes the lead as our top story for 2019. Brexanolone (introduced as SAGE-547 by SAGE Therapeutics) [...]
We completed our first MGH Women’s Mental Health online CME program in the Fall of 2019, and we are excited to offer the next round of the course in the series. Thank you for those [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has been [...]
While earlier observational studies suggested that hormone treatment may improve cognitive functioning in peri- and postmenopausal women, studies from the Women’s Health Initiative (WHI) demonstrated that estrogen replacement therapy started in postmenopausal women (65 years [...]